¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"minimal blocking concentration"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
¿µ¹® concentration ÇÑ±Û ³óµµ, ÁýÁß
¼³¸í   
  1. ³óµµ. ¿ë¾×À̳ª ¿ë¸ÅÀÇ Áú·® ¶Ç´Â Ã¼Àû¿¡ ´ëÇÑ ¿ëÁúÀÇ Áú·® ¶Ç´Â Ã¼Àû. 2. ÁýÁß. °øÅëÀÇ Áß½ÉÀ¸·Î ¸ô¸®´Â ÇÑ Á¡¿¡ ÁýÇÕÇϴ °Í.
¿µ¹® pH, hydrogen ion concentration ÇÑ±Û ¼ö¼ÒÀ̿³óµµÁö¼ö
¼³¸í   
  Ç÷¾×À̳ª ¼Òº¯¿¡¼­ ½Ç½ÃÇϴ °Ë»çÇ׸ñ. pH°Ë»ç´Â ÀÎüÀǠü¾×ÀÇ »ê¼º, ¾ËÄ®¸®¼ºÀ» ¾Ë¾Æº¸´Â Áß¿äÇÑ °Ë»çÀÌ´Ù. ÀÎü´Â ¾à¾ËÄ®¸®¼º¿¡ ¼ÓÇϳª, À̺¸´Ù pHÀÇ Áõ°¡³ª °¨¼Ò°¡ ³ªÅ¸³¯ °æ¿ì, »ý¸í¿¡ À§ÇèÀÌ ¹ß»ýÇÑ´Ù. ÀÎü³»¿¡´Â ÀÌ·± »êµµÀÇ Áõ°¨À» ¸·±âÀ§ÇØ, À̸¥¹Ù ¿ÏÃæÁ¦µéÀÌ ¸¹ÀÌ Á¸ÀçÇϸç, Æ¯È÷ ÇãÆÄ¿Í ÄáÆÏÀÌ ¿ÏÃæÀÛ¿ëÀ» ¼öÇàÇϴ ÁÖ¿ä±â°üÀÌ´Ù.
  
  ÄáÆÏÀº »êµµ°¡ ³ôÀ» °æ¿ì, ¼Òº¯¿¡¼­ »êµµ¸¦ Áõ°¡½ÃÄÑ ¹èÃâÇÔÀ¸·Î½á Ç÷¾×³»ÀÇ ¾ËÄ®¸®¼º ³óµµ°¡ Áõ°¡Çϵµ·Ï ÇÑ´Ù. ¶ÇÇÑ ÇãÆÄ¿¡¼­µµ, Ç÷¾×³»¿¡ »êµµ°¡ Áõ°¡½Ã È£ÈíÀ» Áõ°¡ÇÔÀ¸·Î½á ¹ÛÀ¸·Î »êÀÇ ¹èÃâÀ» Áõ°¡½ÃŲ´Ù. ÀÌ·± ÇãÆÄ¿Í ÄáÆÏÀÇ ±ÕÇüÀº ¾ÆÁÖ ÀûÀýÈ÷ ÀÌ·ç¾îÁö°í ÀÖÀ¸¸ç, ¾î´À ÇÑ ±â°üÀÇ ÀÌ»óÀÌ ¹ß»ýÇϸé, ÀÌ·± ±ÕÇüÀº ±ú¾îÁö±â ½±´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • minimal blocking concentration
    ÃÖ¼ÒÂ÷´Ü³óµµ
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • minimal alveolar concentration
    ÃÖ¼ÒÆóÆ÷³óµµ
  • minimal anesthetic concentration
    ÃÖ¼Ò¸¶Ãë³óµµ
  • minimal bactericidal concentration
    ÃÖ¼Ò»ì±Õ³óµµ
  • minimal effective analgesic concentration
    ÃÖ¼ÒÈ¿°úÁøÅë³óµµ
  • minimal inhibitory concentration
    ÃÖÀú¾ïÁ¦³óµµ
  • autonomic blocking agent
    ÀÚÀ²½Å°æÂ÷´ÜÁ¦
  • adrenergic blocking agent
    ¾Æµå·¹³¯¸°Â÷´ÜÁ¦
  • blocking agent
    Â÷´ÜÁ¦
  • blocking antibody
    Â÷´ÜÇ×ü
  • blocking of thought
    »ç°íµÎÀý
  • cholinergic blocking agent
    Äݸ°Â÷´ÜÁ¦
  • ganglionic blocking agent
    ½Å°æÀýÂ÷´ÜÁ¦
  • minimal
    ÃÖ¼Ò-
  • minimal angle resolution
    ÃÖ¼Ò°¢ºÐÇØ´É
  • minimal brain dysfunction
    °æ¹Ì³ú±â´ÉÀå¾Ö
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • minimal invasive surgery
    ÃÖ¼Òħ½À¼ö¼ú
  • blocking agent
    Â÷´ÜÁ¦
  • blocking antibody
    Â÷´ÜÇ×ü
  • concentration
    ³óµµ, ÁýÁß
  • blood concentration
    Ç÷Áß³óµµ
  • stress concentration
    ÀÀ·ÂÁýÁß
  • blocking of thought
    »ç°íµÎÀý
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • minimal blocking concentration
    ÃÖ¼ÒÂ÷´Ü³óµµ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • minimal alveolar concentration
    ÃÖ¼ÒÆóÆ÷³»³óµµ
  • minimal anesthetic concentration
    ÃÖ¼Ò¸¶Ãë³óµµ
  • minimal bactericidal concentration
    ÃÖ¼Ò»ì±Õ³óµµ
  • minimal effective analgesic concentration
    ÃÖ¼ÒÈ¿°úÁøÅë³óµµ
  • minimal inhibitory concentration
    ÃÖÀú¾ïÁ¦³óµµ, ÃÖÀúÀúÁö³óµµ
  • adrenergic blocking agent
    ¾Æµå·¹³¯¸°Â÷´ÜÁ¦
  • autonomic blocking agent
    ÀÚÀ²½Å°æÂ÷´ÜÁ¦
  • blocking agent
    Â÷´ÜÁ¦
  • blocking antibody
    Â÷´ÜÇ×ü
  • cholinergic blocking agent
    Äݸ°Â÷´ÜÁ¦
  • ganglionic blocking agent
    ½Å°æÀýÂ÷´ÜÁ¦
  • blocking test
    Â÷´Ü½ÃÇè
  • depolarizing neuromuscular blocking drug
    Å»ºÐ±Ø½Å°æ±ÙÂ÷´ÜÁ¦
  • ganglionic blocking drug
    ½Å°æÀýÂ÷´Ü¾àÁ¦
  • minimal visible angle
    Ãּҽð¢
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Kobraks minimal stimulation
    ÄÚºê¶ô¾àÀڱعý
  • Ganglionic blocking drugs
    ½Å°æÀýÂ÷´Ü¾àÁ¦(ãêÌèï½ó´Ó¨å·ð¥)
  • H2 recepor blocking agents, for ulcers
    H2¼ö¿ëüÂ÷´ÜÁ¦(â¥é»ô÷ó´Ó¨ð¥)
  • alpha blocking
    ¾ËÆÄÂ÷´Ü
  • antibody, blocking
    Â÷´ÜÇ×ü
  • ganglionic blocking action
    ½Å°æÀýÂ÷´ÜÀÛ¿ë.
  • ganglionic blocking agent
    ½Å°æÀýÂ÷´ÜÁ¦.
  • genetic blocking
    À¯ÀüÀû Â÷´Ü(ë¶îîîÜó´Ó¨).
  • genetic blocking
    À¯ÀüÀû Â÷´Ü.
  • receptor blocking agent
    ¼ö¿ëüÂ÷´Ü<ºÀ¼â>Á¦.
  • AUC : area under the concentration-time curve
    Ç÷Áß(¾à¹°)³óµµ°î¼±ÇϸéÀû.
  • BAC (blood alcohol concentration)
    Ç÷Áß¾ËÄڿóóµµ
  • Concentration
    ³óµµ(ÒØÓø), ÁýÁß
  • Concentration difference
    ³óµµ±¸¹è(ÒØÓøÏ£ÛÕ), ³óµµ°æ»ç
  • Critical micelle concentration
    ÃÖÀú¹Ì¼¿Çü¼º³óµµ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • minimum blocking concentration
    ÃÖ¼ÒÂ÷´Ü³óµµ
  • minimal bactericidal concentration (MBC)
    »ì±ÕÃÖ¼Ò³óµµ
  • minimal effective analgesic concentration
    ÃÖ¼ÒÈ¿°úÀûÁøÅë³óµµ
  • minimal inhibitory concentration
    ÃÖÀú¹ßÀ°ÀúÁö³óµµ(õÌî¸Û¡ëÀðæò­ÒØöô).
  • adrenergic blocking agent
    ¾Æµå·¹³¯¸°Â÷´ÜÁ¦.
  • adrenergic blocking agent
    ¾Æµå·¹³¯¸°¼º Â÷´ÜÁ¦
  • adrenergic blocking agent
    ¾Æµå·¹³¯¸°(¼º) ºÀ¼â<Â÷´Ü>¾à.
  • alpha blocking
    ¾ËÆÄÂ÷´Ü
  • antibody, blocking
    Â÷´ÜÇ×ü
  • autonomic blocking agent
    ÀÚÀ²½Å°æÂ÷´Ü<ºÀ¼â>Á¦(í»ëÏãêÌèó´Ó¨<Üæáð>ð¥).
  • blocker/blocking agent
    Â÷´ÜÁ¦
  • blocking
    ¸·Èû, ´ÜÀý, Â÷´Ü.
  • blocking agent
    Â÷´ÜÁ¦(ó´Ó¨ð¥).
  • blocking antibody
    Â÷´ÜÇ×ü(ó´Ó¨ù÷ô÷)
  • blocking antibody =blocker
    Â÷´ÜÇ×ü(¡­ù÷ô÷).
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • concentration technique
    Áý¶õ¹ý
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • blocking antibody
    Â÷´ÜÇ×ü(ó´Ó¨ù÷ô÷)
  • blocking group
    Â÷´Ü±â(ó´Ó¨Ðñ)
  • minimal medium
    ÃÖ¼Ò¹èÁö(õÌá³ÛÆò¢)
  • minimal stable length
    ÃÖ¼Ò¾ÈÁ¤(õÌá³äÌïÒ) ±æÀÌ
  • active concentration
    Ȱ¼º³óµµ(üÀàõÒØÓø)
  • concentration
    ³óµµ(ÒØÓø)
  • concentration equilibrium constant
    "³óµµÆòÇü»ó¼ö(ÒØÓøøÁû¬ßÈâ¦), (ÔÒ) apparent equilibrium constant"
  • concentration gradient
    ³óµµ ±¸¹è(ÒØÓøÎþÛÕ)
  • concentration of enzymatic activity
    È¿¼ÒȰ¼º ³óµµ(ý£áÈüÀàõÒØÓø)
  • concentration work
    ³óµµÀÛµ¿(ÒØÓøíÂÔÑ)
  • constituent concentration
    ±¸¼º¹° ³óµµ(ϰà÷ÚªÒØÓø)
  • critical concentration
    "ÀÓ°è³óµµ(×üÍ£ÒØÓø),"
  • critical micelle concentration
    ÃÖÀú(õÌî¸) ¹Ì¼¿ Çü¼º³óµµ(û¡à÷ÒØÓø)
  • effective concentration
    À¯È¿ ³óµµ (êóüùÒØÓø)
  • enzyme concentration
    È¿¼Ò³óµµ (ý£áÈÒØÓø)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • blood concentration
    Ç÷Áõ³óµµ
  • concentration
    ³óµµ, ³óÃà, ÁýÁß
  • minimal
    ÃÖ¼ÒÀÇ
  • minimal effective dose
    ÃÖ¼ÒÀ¯È¿·®
  • minimal enhancement
    ¹Ì¹ÌÇÑÁ¶¿µÁõ°­, °æµµÀÇÁ¶¿µÁõ°­
  • permissible concentration
    Çã¿ë³óµµ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
NMB neuromedin B; neuromuscular blockade; neuromuscular blocking; neuromuscular blocker/blocking [drug, ...
SBF serologic-blocking factor; specific blocking factor; splanchnic blood flow
MIC maternal and infant care; medical intensive care; Medical Interfraternity Conference; microscopy; mi...
MRD maximum rate of depolarization; measles-rindenpest-distemper [virus group]; medical records departme...
MAC MacConkey [broth]; major ambulatory category; malignancy-associated changes; maximum allowable conce...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
MAC Minimal Alveolar Concentration
MBC Minimal Bactericidal Concentration
MIC Minimal Inhibition Concentration
MIC Minimal Inhibitory Concentration
MIC90 Minimal Inhibitory Concentration
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • Eagle`s minimal essential medium
    ÀÌ±Û ¹èÁö
    ¼¼Æ÷ ¹è¾ç¾×ÀÇ ÀÏÁ¾. 3Á¾·ùÀÇ ¾Æ¹Ì³ë»ê°ú 8Á¾·ùÀÇ ºñŸ¹ÎÀ» ÇÔÀ¯Çϰí ÀÖÀ¸¸ç º¸Åë Ç÷û 5% ÀÌÇÏ¿¡¼­ À¯Áö ¹èÁö·Î¼­ »ç¿ëµÇ°í 10-20%ÀÇ Ç÷û ÷°¡·Î ¸¹Àº ¼¼Æ÷´Â ±ØÈ÷ ¾çÈ£ÇÑ ¹ßÀ°À» ³ªÅ¸³½´Ù.
  • minimal
    ÃÖ¼ÒÀÇ
    °¡Àå °¡´É¼ºÀÌ ÀûÀº.
  • minimal dose
    ÃÖ¼Ò·®
  • minimal enhancement
    ¹Ì¹ÌÇÑ Á¶¿µ Áõ°­, °æµµÀÇ Á¶¿µ Áõ°­
  • minimal identifiable odor
    ÃÖ¼Ò ºÐÇØ Ãë°¢
  • minimal requirement
    ÃÖ¼Ò ±Ô°Ý
  • minimal temperature
    ÃÖÀú ¿Âµµ
  • adrenergic blocking agent
    ¾Æµå·¹³¯¸° Â÷´ÜÁ¦
    ¾Æµå·¹³¯¸°¼º ¼ö¿ëü¿¡ ÀÛ¿ëÇÏ¿© ½Å°æ Àü´Þü¿Í ¼ö¿ëü°¡ °áÇÕÇÏÁö ¸øÇÏ°Ô ÇÔÀ¸·Î½á ±³°¨½Å°æ ÈïºÐ È¿°ú¸¦ ºÀ¼âÇÏ´Â ¾à¹°.
  • autonomic blocking agent
    ÀÚÀ² ½Å°æ Â÷´ÜÁ¦
  • beta-adrenergic blocking agent
    º£Å¸ ¾Æµå·¹³¯¸°¼º Â÷´ÜÁ¦
  • blocking
    Â÷´Ü, ºÀ¼â, Â÷´Ü¾à, ºÀ¼â¾à, Á¡Âø
    1. ±¸½É¼º ½Å°æ·ÎÀÇ Â÷´Ü, ¿¹ÄÁµ¥ ÄÚÄÉÀÎ ÁÖ»ç·Î ÀÎÇÑ Â÷´Ü. ¼¼Æ÷³» »ýÇÕ¼º °úÁ¤ÀÇ ÀúÁö. 2. ¾î¶² ÄÞÇ÷º½º¿¡ ºÎµúÃÆÀ» ¶§ °©ÀÛ½º·± ¿¬»óÀÇ Á¤Áö¿¡ ´ëÇÑ ÇÁ·ÎÀ̵åÇÐÆÄÀÇ ¿ë¾î. 3. ¼¿·ÎÀ̵òÀ¸·Î ħÅõ½ÃŲ Á¶Á÷ Ç¥º»À» ¸ñÆíÀ̳ª ±âŸ ´Ù¸¥ Àû´çÇÑ ¹°Áú·Î °íÁ¤½ÃÄÑ ¸¶ÀÌÅ©·ÎÅè¿¡ ºÎÂø½Ãų ¼ö ÀÖ°Ô ÇÏ´Â °Í.
  • blocking antibody
    Â÷´Ü Ç×ü
    µ¿ÀǾî=blocker.
  • blocking effect
    Â÷´Ü È¿°ú
  • blocking of thought
    »ç°íÀúÇØ
    Á¤½ÅºÐ¿­Áõ¿¡¼­ º¼ ¼ö ÀÖ´Â °ÍÀ¸·Î¼­ ȯÀÚÀÇ È£¼Ò´ë·Î »ç°íÀÇ ±æÀÌ ¸·Çô¼­ ÀÚ½ÅÀ» Ç¥ÇöÇÏ´Â °ÍÀÌ ¾î·Á¿î Á¤½Å »óÅÂ.
  • calcium channel blocking drug
    Ä®½· Åë·Î ºÀ¼â ¾à¹°, Ä®½· Åë·Î Â÷´Ü ¾à¹°
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
minimal alveolar concentration The end-alveolar concentration of an inhalation anaesthetic which prevents somatic response to a painful stimulus in 50% of individuals; an index of relative potency of inhalation anaesthetics.
Synonym: minimal anaesthetic concentration.
(05 Mar 2000)
minimal anaesthetic concentration The end-alveolar concentration of an inhalation anaesthetic which prevents somatic response to a painful stimulus in 50% of individuals; an index of relative potency of inhalation anaesthetics.
Synonym: minimal anaesthetic concentration.
(05 Mar 2000)
minimal inhibitory concentration <microbiology, pharmacology> The lowest concentration of antibiotic sufficient to inhibit bacterial growth when tested in vitro.
(05 Mar 2000)
minimal Smallest or least, the smallest possible.
Origin: L. Minimus = least
(18 Nov 1997)
minimal air The volume of gas that remains in the lungs and cannot be expelled after they have been removed from the body, or after the chest has been opened.
(05 Mar 2000)
minimal amplitude nystagmus Nystagmus of so small an amplitude that it is not detected by the usual clinical tests.
Synonym: minimal amplitude nystagmus.
Origin: micro-+ G. Nystagmos, a nodding
(05 Mar 2000)
minimal brain dysfunction An inability to control behaviour due to difficulty in processing neural stimuli.
(12 Dec 1998)
minimal-change disease <nephrology> A disorder of the kidneys which largely affects the glomerulus, the blood filtering structure.
This disorder is one common cause of nephrotic syndrome, minimal glomerular changes, in children affecting 2 to 3 children per 100,000 population under age 16 in the USA. Minimal change disease is also seen rarely in adults. The cause is unknown but may be related to an autoimmune illness.
It is marked by oedema, albuminuria, and an increase in cholesterol in the blood, but otherwise with fairly good renal function. Tubular epithelium is vacuolated by cholesterol droplets, but the glomeruli show only that the foot processes of the glomerular epithelial cells are fused, probably secondary to the proteinuria; the cause of the increased glomerular permeability to plasma protein is unknown.
Risk factors include a history for a immune disorder, recent immunisation or a bee sting.
Diagnosis is made by renal biopsy.
Treatment include systemic corticosteroids which are usually quite effective in curing this disease. Other medications include chlorambucil and cyclophosphamide. In most cases, a moderate protein diet (1 gram protein per Kg body weight per day) will be recommended. Salt (sodium) restriction can be helpful to reduce swelling and vitamin D is usually supplemented.
Synonym: lipoid nephrosis
(27 Sep 1997)
minimal-change nephrotic syndrome <nephrology> A disorder of the kidneys which largely affects the glomerulus, the blood filtering structure.
This disorder is one common cause of nephrotic syndrome, minimal glomerular changes, in children affecting 2 to 3 children per 100,000 population under age 16 in the USA. Minimal change disease is also seen rarely in adults. The cause is unknown but may be related to an autoimmune illness.
It is marked by oedema, albuminuria, and an increase in cholesterol in the blood, but otherwise with fairly good renal function. Tubular epithelium is vacuolated by cholesterol droplets, but the glomeruli show only that the foot processes of the glomerular epithelial cells are fused, probably secondary to the proteinuria; the cause of the increased glomerular permeability to plasma protein is unknown.
Risk factors include a history for a immune disorder, recent immunisation or a bee sting.
Diagnosis is made by renal biopsy.
Treatment include systemic corticosteroids which are usually quite effective in curing this disease. Other medications include chlorambucil and cyclophosphamide. In most cases, a moderate protein diet (1 gram protein per Kg body weight per day) will be recommended. Salt (sodium) restriction can be helpful to reduce swelling and vitamin D is usually supplemented.
Synonym: lipoid nephrosis
(27 Sep 1997)
minimal deviation melanoma <dermatology, tumour> A malignant melanoma showing less cytologic atypia than is usual in melanoma cells showing asymmetric expansile invasion of the dermis.
(05 Mar 2000)
minimal dose <pharmacology> The smallest amount of a drug or physical procedure that will produce a desired physiologic effect in an adult.
(05 Mar 2000)
minimal infecting dose <microbiology> The smallest quantity of infectious material regularly producing infection; usually expressed as I.D.50, the quantity causing infection in 50% of a suitable series of animals or cells (cell cultures).
(05 Mar 2000)
minimal lethal dose <pharmacology> The minimal dose of a toxic substance or infectious agent that is lethal, as assayed in various experimental animals (e.g., the least amount of diphtheria toxin that, on an average, kills a 250-g guinea pig within 96 hours after subcutaneous inoculation).
When followed by a subscript (generally "MLD50"), denotes the minimal dose that is lethal to a certain percentage (e.g., 50%) of animals so assayed, LD05.
See: lethal dose.
(05 Mar 2000)
minimal medium <cell culture> The simplest tissue culture medium that will support the proliferation of normal cells.
(18 Nov 1997)
minimal reacting dose The minimal dose of a toxic substance causing a reaction, as manifested in the skin of a series of susceptible test animals; the assay is based on the development of a characteristic, minimal but definite, "standard," focal inflammation (congestion and oedema, induration, degenerative changes, and desquamation of epidermal cells).
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • blocking
    ¿À¸®´ë(Æ´À» ¸Þ¿ì´Â ³ª¹µÁ¶°¢);ºí·ÎÅ·;ÀúÁö Çö»ó(¹Ù¶÷Á÷ÇÏÁö ¾ÊÀº »ó³ä¿¡ ÀÇÇÑ ¿¬»ó Áß´Ü);(¹è¿ìÀÇ)¿¬Ãâ;ºí·ÎÅ·Çϱâ
  • concentration
    ÁýÁß; Àü³ä
  • concentration
    ÁýÁß;Áý°á;Àü½ÉÀü·Â;ÁýÁß·Â;Àü·Å;³óÃà;(¾×üÀÇ)³óµµ;¼±±¤;³óÈ­;ÁýÁß¿¬±¸;¼ýÀÚ¸ÂÃ߱⠳îÀÌ
  • concentration camp
    Á¤Ä¡¹ü(Æ÷·Î)¼ö¿ë¼Ò
  • minimal
    ±Ø¼ÒÀÇ; ÃÖÀúÀÇ
  • minimal
    ÃÖ¼ÒÇâ(¼ö)ÀÇ;±Ø¼ÒÀÇ
  • minimal art
    ¹Ì´Ï¸Ö ¾ÆÆ®;ÃÖ¼ÒÇÑÀÇ Á¶Çü ¼ö´ÜÀ¸·Î Á¦ÀÛµÈ ±×¸²;Á¶°¢
  • minimal brain dysfunction
    ¹Ì¼Ò ³ú±â´É Àå¾Ö (¾Æµ¿ÀÇ ÇнÀ Àå¾ÖÀÇ Çϳª)
  • minimal pair
    ÃÖ¼Ò ´ë¾î(bet¿Í bed ó·³ °°Àº À§Ä¡ÀÇ ÇÑ °¡Áö ¼Ò¸®¸¸ ´Ù¸¥ ÇÑ ½ÖÀÇ ³¹¸»)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á